Skip to main content

Adicet Bio Inc

For the period ended Dec 31, 2023. Filed Mar 19, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 19, 2024

ACET$3.00+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

POWER OF ATTORNEY

Each person whose individual signature appears below hereby authorizes and appoints Chen Schor and Nick Harvey, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Chen Schor
Chen SchorPresident, Chief Executive Officer and Director (principal executive officer)March 19, 2024
/s/ Nick Harvey
Nick HarveyChief Financial Officer (principal financial officer and principal accounting officer)March 19, 2024
/s/ Jeffrey Chodakewitz
Jeffrey Chodakewitz, M.D.DirectorMarch 19, 2024
/s/ Steve Dubin
Steve DubinDirectorMarch 19, 2024
/s/ Carl L. Gordon
Carl L. Gordon, Ph.D.DirectorMarch 19, 2024
/s/ Aya Jakobovits
Aya Jakobovits, Ph.D.DirectorMarch 19, 2024
/s/ Michael Kauffman
Michael Kauffman, M.D., Ph.DDirectorMarch 19, 2024
/s/ Katie Peng
Katie PengDirectorMarch 19, 2024
/s/ Andrew Sinclair
Andrew Sinclair, Ph.D.DirectorMarch 19, 2024
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.